- Home
- YQ vs PRPO Comparison
YQ vs PRPO Comparison
Compare YQ & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- PRPO
- Stock Information
- Founded
- YQ 2012
- PRPO N/A
- Country
- YQ China
- PRPO United States
- Employees
- YQ N/A
- PRPO N/A
- Industry
- YQ Other Consumer Services
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- YQ Real Estate
- PRPO Industrials
- Exchange
- YQ Nasdaq
- PRPO Nasdaq
- Market Cap
- YQ 12.1M
- PRPO 12.3M
- IPO Year
- YQ 2020
- PRPO N/A
- Fundamental
- Price
- YQ $2.06
- PRPO $10.14
- Analyst Decision
- YQ
- PRPO
- Analyst Count
- YQ 0
- PRPO 0
- Target Price
- YQ N/A
- PRPO N/A
- AVG Volume (30 Days)
- YQ 9.2K
- PRPO 13.1K
- Earning Date
- YQ 03-19-2025
- PRPO 03-28-2025
- Dividend Yield
- YQ N/A
- PRPO N/A
- EPS Growth
- YQ N/A
- PRPO N/A
- EPS
- YQ N/A
- PRPO N/A
- Revenue
- YQ $28,507,378.00
- PRPO $17,411,000.00
- Revenue This Year
- YQ N/A
- PRPO $75.18
- Revenue Next Year
- YQ N/A
- PRPO N/A
- P/E Ratio
- YQ N/A
- PRPO N/A
- Revenue Growth
- YQ 22.55
- PRPO 31.31
- 52 Week Low
- YQ $1.50
- PRPO $4.31
- 52 Week High
- YQ $3.20
- PRPO $10.74
- Technical
- Relative Strength Index (RSI)
- YQ 63.62
- PRPO 85.00
- Support Level
- YQ $1.93
- PRPO $7.02
- Resistance Level
- YQ $2.08
- PRPO $7.54
- Average True Range (ATR)
- YQ 0.08
- PRPO 0.50
- MACD
- YQ 0.01
- PRPO 0.29
- Stochastic Oscillator
- YQ 89.61
- PRPO 85.72
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.